Annexon Biosciences: Funding, Investors & Team (Oct 2026)

Annexon is a clinical-stage biopharmaceutical organization fostering a pipeline of novel treatments for patients with traditional supplement interceded problems of the body, mind and eye. The organization's pipeline depends on its foundation innovation tending to well-informed traditional supplement interceded immune system and neurodegenerative infection processes, the two of which are set off by variant enactment of C1q, the starting atom of the old style supplement pathway. The organization's most memorable item competitor, ANX005, is a full-length monoclonal immune response figured out for intravenous organization in immune system and neurodegenerative problems. The organization's second item up-and-comer, ANX007, is a monoclonal immunizer Fab formed for intravitreal organization for the treatment of neurodegenerative ophthalmic problems. Annexon is propelling its ongoing projects while assessing extra vagrant and enormous market signs. Annexon is conveying a trained, biomarker-driven improvement methodology intended to lay out that its item up-and-comers are drawing in the objective at a very much endured helpful portion in the planned patient tissue.

Annexon Biosciences has raised $230M across 2 rounds on record. The most recent is a Post-IPO Equity of $130M announced in Jul 2022.

Annexon Biosciences' most recent funding round on record is a Post-IPO Equity of $130M, announced in Jul 2022.

Doug Love is listed as CEO at Annexon Biosciences.

Annexon Biosciences is based in South San Francisco, California, United States.

Annexon Biosciences is in the 101-250 employee band.

Annexon Biosciences' latest round of $130M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.